Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ

This study has been terminated.
(This study was terminated when the accrual goal for the low/intermediate grade stratum was reached. The high grade stratum was closed due to slow accrual.)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
First received: November 1, 1999
Last updated: October 6, 2015
Last verified: October 2015

November 1, 1999
October 6, 2015
April 1997
December 2007   (final data collection date for primary outcome measure)
Actuarial local recurrence rate [ Time Frame: Assessed at 5 years ] [ Designated as safety issue: No ]
Rate of in situ or invasive local breast cancer recurrence
Not Provided
Complete list of historical versions of study NCT00002934 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Local Excision Alone for Selected Patients With DCIS of the Breast

RATIONALE: The evaluation of breast cancer recurrence rates may improve the ability to plan cancer treatment for patients with breast cancer.

PURPOSE: Study to evaluate the rate of recurrence of breast cancer in women who have had surgery for ductal carcinoma in situ.


  • Evaluate actuarial local in situ and invasive recurrence rates at 5 and 10 years after local excision in women with a favorable ductal carcinoma in situ (DCIS) prognosis.
  • Evaluate concordance between institutional pathologists and central review pathologists with respect to diagnosis and grading of DCIS.
  • Identify parameters that indicate increased or decreased risk of recurrence in the absence of irradiation.
  • Evaluate patterns of salvage of recurrence and rates of breast conservation.
  • Evaluate actuarial relapse-free, overall, and cause-specific survival at 5 and 10 years post DCIS excision.

OUTLINE: This is a registration study stratified by histologic grade (high vs low or intermediate) and adjuvant tamoxifen therapy (yes vs no).

Patients receive standard clinical and mammographic follow-up for greater than 10 years. If recurrence occurs, treatment will be at the discretion of the investigators. Patients may receive adjuvant oral tamoxifen daily for 5 years after local excision.

A follow up magnification view mammogram must be taken after the last local excision, and microcalcification must be negative.

Patients are followed every 6 months for the first 10 years, and then annually thereafter.

PROJECTED ACCRUAL: 1000 (500 per stratum) eligible and evaluable patients will be enrolled at an estimated accrual rate of 250 patients per year.

Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Breast Cancer
Procedure: long-term screening
No Intervention: Pathology Review, Observation and Follow-up
Pathology review, observation and follow-up
Intervention: Procedure: long-term screening

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
October 2012
December 2007   (final data collection date for primary outcome measure)


  • Histologically proven low or intermediate grade ductal carcinoma in situ (DCIS) of the breast

    • No greater than 2.5 cm in the greatest dimension
  • OR
  • Histologically proven high-grade DCIS of the breast

    • No greater than 1 cm in greatest dimension
  • Region of DCIS must be at least 2.5 mm in greatest dimension (mammographic estimate of size allowed where pathologic measurement is impossible)
  • DCIS must be non-palpable; detected by a mammogram or found incidentally by a breast biopsy
  • Pathologically confirmed negative margins of at least 3 mm
  • Breast must be suitable for breast conserving therapy

    • Proper tumor size versus breast size
    • No carcinoma or suspicious mammogram findings in other breast sites
  • No prior in situ or invasive breast cancer
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Female

Menopausal status:

  • Not specified

Performance status:

  • Not specified

Life expectancy:

  • Greater than 5 years


  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • No other invasive malignancies within the past 10 years except nonmelanomatous skin cancer or carcinoma in situ of the cervix
  • No known HIV infection
  • No Paget's nipple disease


Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • Adjuvant tamoxifen allowed


  • No prior radiotherapy to breast
  • No adjuvant radiotherapy


  • Not specified
18 Years to 120 Years
Contact information is only displayed when the study is recruiting subjects
United States,   South Africa
CDR0000065370, U10CA021115, E-5194
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Study Chair: Lorie L. Hughes, MD Winship Cancer Institute of Emory University
Eastern Cooperative Oncology Group
October 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP